Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protamine 3 is a small, arginine-rich protein expressed in the late stages of spermatogenesis. Its main function is to substitute for histones in sperm chromatin, compacting DNA into a highly condensed and genetically inactive state. This condensation is essential for sperm head morphology and genome stability. Although gene clusters for protamines P1 and P2 are well characterized in mammals, PRM3 (sometimes called 'gene 4') is predicted to have a composition rich in negatively charged amino acids, distinguishing it from other protamines that are positively charged. PRM3 is associated with sperm structure and motility, and mutations may be implicated in male infertility[1][2][3]. No evidence supports PRM3 as a clinically actionable therapeutic target, nor are drugs, biomarkers, or safety issues associated with this molecule currently known.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protamine 3 (PRM3).